Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma

Edoardo G. Giannini, Alessandro Moscatelli, Gaia Pellegatta, Alessandro Vitale, Fabio Farinati, Francesca Ciccarese, Fabio Piscaglia, Gian Lodovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Giuseppe Cabibbo, Martina Felder, Rodolfo Sacco, Filomena Morisco, Gabriele Missale, Francesco Giuseppe Foschi, Antonio Gasbarrini, Gianluca Svegliati BaroniRoberto Virdone, Alberto Masotto, Franco Trevisani, Luigi Bolondi, Maurizio Biselli, Paolo Caraceni, Alessandro Cucchetti, Marco Domenicali, Annagiulia Gramenzi, Donatella Magalotti, Anna Pecorelli, Carla Serra, Laura Venerandi, Alessia Gazzola, Francesca Murer, Caterina Pozzan, Veronica Vanin, Paolo Del Poggio, Stefano Olmi, Claudia Balsamo, Elena Vavassori, Luisa Benvegnù, Alberta Capelli, Rita Golfieri, Cristina Mosconi, Matteo Renzulli, Giulia Bosco, Paola Roselli, Serena Dell'Isola, Anna Maria Ialungo, Elena Rastrelli, Antonino Picciotto, Vincenzo Savarino, Andrea Mega, Emanuele Rinninella, Valeria Mismas, Arianna Lanzi, Federica Mirici Cappa, Alessandro Musetto, Elga Neri, Giuseppe Francesco Stefanini, Alessandra Suzzi, Stefano Tamberi, Omero Triossi, Maria Chiaramonte, Fabiana Marchetti, Matteo Valerio

Research output: Contribution to journalArticle

Abstract

OBJECTIVES:The Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC B) includes a heterogeneous population of patients with hepatocellular carcinoma (HCC). Recently, in order to facilitate treatment decisions, a panel of experts proposed to subclassify BCLC B patients. In this study, we aimed to assess the prognostic capability of the BCLC B stage reclassification in a large cohort of patients with untreated HCC managed by the Italian Liver Cancer Group.METHODS:We assessed the prognosis of 269 untreated HCC patients observed in the period 1987-2012 who were reclassified according to the proposed subclassification of the BCLC B stage from stage B1 to stage B4. We evaluated and compared the survival of the various substages.RESULTS:Median survival progressively decreased from stage B1 (n=65, 24.2%: 25 months) through stages B2 (n=105, 39.0%: 16 months) and B3 (n=22, 8.2%: 9 months), to stage B4 (n=77, 28.6%: 5 months; P

Original languageEnglish
Pages (from-to)70-77
Number of pages8
JournalAmerican Journal of Gastroenterology
Volume111
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Giannini, E. G., Moscatelli, A., Pellegatta, G., Vitale, A., Farinati, F., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Cabibbo, G., Felder, M., Sacco, R., Morisco, F., Missale, G., Foschi, F. G., Gasbarrini, A., ... Valerio, M. (2016). Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma. American Journal of Gastroenterology, 111(1), 70-77. https://doi.org/10.1038/ajg.2015.389